Posts Tagged ‘diabesity’

Oral Semaglutide: Diabesity Business As Usual Is Doomed

February 23, 2018 — Wachet auf! As if the clues were not already present, an announcement yesterday makes it plain. Competitors in the sleepy diabesity market had best wake up. The first ever oral GLP-1 agonist for diabetes and obesity – semaglutide – is looking good in clinical trials. That means everyone else had better get serious about innovation. Or risk becoming […]

High Hopes for a New Diabesity Drug

August 18, 2017 — Call us superstitious. The hopes for a new diabesity drug – semaglutide – are growing higher. And to us, that’s a good news, bad news story. The high hopes are coming from good clinical results for this new GLP-1 agonist in a head-to-head comparison with dulaglutide from Eli Lilly. Dulaglutide is a GLP-1 activator that’s already on […]